Today Engility Holdings announced it was awarded a $112 million single-award indefinite delivery/indefinite quantity (IDIQ) contract by the Food and Drug Administration (FDA) Scientific Computing Board and Office of Information Management and Technology (OIMT). Engility will deliver services unique to computational science and bioinformatics, a discipline that promotes gene-based drug discovery and development.
With this award, Engility expands on our long-standing partnership with the FDA to further develop their high performance computing and complex data analysis capabilities,” said Engility CEO Lynn Dugle. “We look forward to supporting the FDA’s mission to make groundbreaking treatments, such as genetics-based medicine, available to all Americans.”
Through this contract, Engility will:
- Deliver services unique to computational science and bioinformatics
- Help the FDA build fast, reliable and adaptable high performance computing architectures that accommodate analyses of complex data sets
- Enable better insights through faster, better-informed regulatory decisions and secure collaboration among FDA scientists and the worldwide scientific community
The services Engility provides under the contract will enable better insights through faster, better-informed regulatory decisions and secure collaboration among FDA scientists and the worldwide scientific community. Engility will work with the Office of Acquisition & Grants Services, FDA Centers and OIMT leadership to apply scientific computing to regulatory-science innovations.
The 5-year award, made in the third quarter of 2016, more than doubles the predecessor $50 million scientific computing IDIQ, where Engility was also the sole holder. The expanded scope signals an increased reliance on scientific computing as an enabler for FDA’s mission.